Weight Loss / GLP-1

Retatrutide

A triple receptor agonist studied across GIP, GLP-1 and glucagon signalling pathways.

Research domain: Weight Loss
Presentation: 10 mg / vial
Assayed purity: 99.38%
Evidence base: Emerging

Also designatedTriple agonist · LY3437943 · Reta · GLP-1 triagonist

Weight LossVerified

Quick facts

Purity specification: ≥ 99% by HPLC
Physical form: Lyophilised powder
Presentation: 10 mg / vial
Evidence base: Emerging
Intended use: Laboratory research only

Current batch · EVN-RETA-2605

Assayed purity99.38%

98%Spec ≥ 99%100%

Northgate Bioanalytical, 14 May 2026. Assayed content 9.87 mg / 10 mg.

View certificate

Enquire Now

Research overview

How it is characterised

Retatrutide is a synthetic peptide characterised in the literature as a single molecule with agonist activity at three distinct receptors: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. The triple-agonist architecture is studied for the way concurrent glucagon receptor engagement modifies energy expenditure signalling relative to dual and single agonists.

Mechanism

Characterised as engaging GIPR, GLP-1R and GCGR from one backbone. The glucagon arm is examined for hepatic effects on lipid handling and for its contribution to energy expenditure, which distinguishes the pharmacology from incretin-only agonists that act principally on insulin secretion and appetite pathways.

Applications

Multi-receptor mechanism research
Energy expenditure model characterisation
Comparative agonist profiling
Preclinical metabolic investigation

Research focus

Areas of published investigation

The following describe where this compound has been examined in the scientific literature. They are not claims of effect, and nothing here should be read as a therapeutic indication.

01Triple receptor agonism

02Glucagon receptor contribution to energy signalling

03Comparative incretin pharmacology

04Hepatic lipid metabolism pathways

Research compatibility

Frequently co-studied

Compounds that appear alongside Retatrutide in the published record, and the reason the literature examines them together.

Included in research stacks

Metabolic Protocol

Molecular & pharmacokinetic data

The physical record

Verify every figure against the certificate of analysis for the batch you hold. Where the label and the assay disagree, the assay is the number to calculate from.

CAS number: 2381089-83-2
Molecular formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molar mass: ≈ 4731.40 g/mol
Reported half-life: ≈ 144 h (reported)
Solubility: Soluble in bacteriostatic water and sterile saline

Analytical record

Batch EVN-RETA-2605

Analysed by Northgate Bioanalytical, ISO/IEC 17025 accredited, under accession NGB-26-0552. The certificate is retrievable from the issuing laboratory independently of us.

Full certificate

Retention time (min)RP-HPLC · UV 214 nm

Purity: 99.38%RP-HPLC, UV 214 nm · spec ≥ 99.0%
Identity: 4731.6 Da (theoretical 4731.4)ESI-MS · spec Conforms to theoretical mass
Assayed content: 98.7% of labelRP-HPLC against reference standard · spec 95.0 – 110.0% of label
Water content: 4.6%Karl Fischer titration · spec ≤ 8.0%
Residual solvents: Acetonitrile 131 ppm; TFA 84 ppmHeadspace GC-FID · spec Within USP <467> limits
Appearance: White to off-white lyophilised cakeVisual inspection · spec Conforms

Storage

Store lyophilised at −20 °C, protected from light and moisture. Following reconstitution, hold at 2–8 °C and use within the interval stated on the batch certificate of analysis.

Handling

Allow the vial to reach ambient temperature before breaking the seal so atmospheric moisture does not condense onto the cake. Introduce diluent slowly against the vial wall rather than directly onto the powder, and swirl rather than shake. Avoid repeated freeze-thaw cycles; aliquot where a preparation will be drawn on more than once.